Inositol: uses, evidence, dosing and safety

Most pages on this site cover a supplement sold for a dozen things that works for one or none. Inositol is the opposite: a narrow compound with two uses, both reasonably well studied, both in women’s health.

It is also one of the few supplements here where the research question is not whether it does anything, but how much and for whom.

What inositol is

Inositol is a small sugar-like molecule the body makes for itself and also absorbs from food: fruit, beans, grains and nuts are the usual sources.

Older labels call it vitamin B8. It is not a vitamin, because the body synthesizes it, and the name has largely been dropped.

Two forms matter. Myo-inositol is the common one and the one in nearly all the pregnancy research. D-chiro-inositol is a converted form, and the two appear together in many polycystic ovary syndrome products.

How inositol works

Inositol sits inside the machinery that carries insulin’s signal into a cell.

When insulin binds to its receptor, the message has to be relayed inward, and inositol-containing molecules are part of that relay. In insulin resistance, that relay works poorly, and there is evidence that inositol handling is altered in the conditions on this page.

That mechanism explains why one compound turns up in two apparently different places. Gestational diabetes and polycystic ovary syndrome are both, at their metabolic core, disorders of insulin signaling.

It also sets the expectation correctly. Inositol is not a hormone or a drug; it is a substrate in a signaling pathway, which is why the effects below are meaningful but not dramatic.

What the evidence says about inositol and gestational diabetes

Its best use, and the evidence has strengthened over the last two years.

A 2026 analysis concluded that myo-inositol supplementation in pregnancy or preconception lowers the risk of gestational diabetes mellitus in women without preexisting diabetes, describing it as a promising, safe, and accessible preventive strategy for gestational diabetes.

A separate 2026 review found a large reduction in the risk of gestational diabetes, and a reduced rate of neonatal hypoglycemia. That is the low blood sugar which can affect babies born to mothers with the condition.

It also moved the expected intermediate measures: ISL significantly lowered oral glucose tolerance test results, fasting blood sugar levels, and birth weight, ISL being the abbreviation the authors use for inositol.

A third 2025 analysis agrees on prevention and adds a detail. A reduction in cesarean section rates was observed, plus lower birth weight. It found no effect on neonatal hypoglycemia or on gestational age.

Note that the reviews disagree on neonatal hypoglycemia. That is the kind of inconsistency worth naming rather than smoothing over, and it is what the certainty ratings below are about.

What Cochrane adds

Cochrane’s assessment is the most careful and the most useful, because it is positive and unsatisfied at once.

It describes myo-inositol as a promising antenatal intervention for preventing gestational diabetes, and encourages further studies.

Then the rating: the reviewers downgraded the certainty of the evidence for many outcomes to low or very low certainty.

Their request is specific, and it describes what is missing across this whole field. They ask for trials including pregnant women of different ethnicities and varying risk factors. They want myo-inositol tested at different doses, frequency and timing of administration. And they want it compared against placebo, diet and exercise, and pharmacological interventions, with outcomes that include potential harms, including adverse effects.

Almost every trial so far has been small, short, and in a single population.

What the evidence says about inositol for treating gestational diabetes

A separate question from prevention, and the answer is weaker.

Cochrane’s review of myo-inositol as a treatment once the condition is diagnosed found the evidence insufficient to reach firm conclusions, and asks that future trials should report on the core outcomes for GDM, GDM meaning gestational diabetes mellitus, and explore the optimal dose, frequency and timing of supplementation.

The 2025 analysis lands in the same place. Its therapeutic effects in women diagnosed with GDM require further validation.

The distinction matters practically. Taking inositol before or early in pregnancy to reduce the chance of developing gestational diabetes has decent support. Taking it after a diagnosis, instead of the dietary and monitoring plan that follows, does not.

What the evidence says about inositol and polycystic ovary syndrome

Its second use, and the honest position is that the biochemistry responds better than the symptoms.

A 2026 analysis found that inositol supplementation is associated with improvements in biochemical hyperandrogenism in women with PCOS, hyperandrogenism meaning raised male-type hormones, which drive several of the condition’s most distressing features.

The interesting finding is who responded. There was evidence of phenotype-dependent variability, and the most consistent biochemical response was observed in normal-weight individuals.

That is unexpected. You would predict that a compound acting on insulin signaling helps most where insulin resistance is worst. The data ran the other way.

The authors are careful about how far it goes. They describe their work as a metabolically informed, hypothesis-generating framework and call for trials measuring things patients experience: standardized measures of hirsutism, ovulatory function, and patient-reported endpoints.

Hirsutism is unwanted hair growth. Ovulatory function determines whether someone can conceive. Neither has been shown to improve, and both are what women with the condition actually want addressed.

What the evidence says about inositol against metformin

Included because it is the comparison most often made and least often supported.

Cochrane’s review of insulin-sensitizing drugs in polycystic ovary syndrome covers metformin and D-chiro-inositol together.

Its findings concern metformin rather than inositol. On fertility, it reports that clomiphene citrate remains preferable to metformin for ovulation induction in obese women with PCOS, and that combined therapy may be useful though we do not know whether this translates into increased live births.

On tolerability it is direct: women taking metformin alone or with combined therapy should be advised that there is no evidence of increased miscarriages, but gastrointestinal side effects are more likely.

That last point is the honest basis for inositol’s popularity. Metformin works and a substantial minority cannot tolerate it. Inositol is easier to take. No trial covered here shows the two are equivalent, and a supplement being gentler is not evidence that it is as effective.

Myths about inositol, and what the evidence says

“Inositol is vitamin B8.” The body makes it, so it is not a vitamin. The name persists on labels and nowhere in current nutrition science.

“It treats gestational diabetes.” The evidence supports preventing it. Cochrane found the treatment evidence insufficient for firm conclusions.

“It is a natural alternative to metformin.” No trial here compares them for the outcomes that matter. It is better tolerated, which is a different claim.

“It cures polycystic ovary syndrome.” It improves hormone markers. Hirsutism and ovulation, the things women mainly want changed, have not been shown to improve.

“The 40:1 ratio is the clinically proven formula.” That ratio reflects the proportions of the two forms in the body, not a head-to-head trial establishing it as optimal.

Dosing and forms of inositol

Pregnancy trials generally use around 2 to 4 grams a day of myo-inositol, usually started before conception or in the first trimester, which is when the prevention evidence applies.

Polycystic ovary syndrome products commonly pair myo-inositol with D-chiro-inositol at 40:1. That figure comes from the ratio found in the body rather than from a trial comparing ratios.

The reviews are explicit that this is unsettled: subgroup analyses indicated that the effects varied based on the type of intervention and dosage of ISL used, and Cochrane asks specifically for trials comparing different doses, frequency and timing.

It comes as a powder more often than a tablet, because the doses are grams rather than milligrams.

Safety, side effects and who should be careful

Inositol is well tolerated in the trials conducted so far, and its safety profile is part of why it is being investigated in pregnancy at all, where the bar is high.

Mild digestive upset, nausea and loose stools appear at higher doses, as with most gram-level supplements.

The honest limit is that Cochrane asks future trials to report on adverse effects and assess the long-term effects of this intervention, which means the safety record rests on short studies rather than long ones.

Anyone pregnant, trying to conceive, or being treated for polycystic ovary syndrome should decide about this with their clinician. That is not a formality here: gestational diabetes is monitored for good reasons, and a supplement is not a substitute for that monitoring.

Interactions

Inositol has no well-documented drug interactions, which is unusual enough to state plainly.

The consideration that matters is additive rather than chemical. Anyone taking metformin or another insulin-sensitizing drug is combining two things aimed at the same pathway, and that is a conversation with whoever prescribed the first one.

Anyone monitoring blood sugar should expect readings to change if inositol is doing what the trials suggest.

Bottom line on inositol

Inositol is a rarity in this library: a supplement with a narrow claim, real evidence behind it, and no attempt to be everything.

For a woman at risk of gestational diabetes, taking myo-inositol before or early in pregnancy has repeated meta-analyses behind it and a Cochrane review calling it promising. The certainty is low, the trials are small, and it is still among the better-supported preventive supplements on this site.

For polycystic ovary syndrome the picture is more partial. The hormone markers move, most consistently in normal-weight women, and the symptoms that bring people to a doctor have not yet been shown to.

The comparison with metformin is where care is needed. Being easier to tolerate is a genuine advantage and it is not the same as working as well, and nobody has run the trial that would settle it.